Introduction of hypoxia-targeting p53 fusion protein for the selective therapy of non-small cell lung cancer

Cancer Biology and Therapy

Volumn 11, Issue 1, 2011, Pages 95-107

  Zhao, Yu ^a   Wu, Shaoping ^b   Wu, Junhua ^a   Jia, Peiyuan ^a   Gao, Shan ^b   Yan, Xiangdong ^b   Wang, Yuxia ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b Beijing Center of Disease Prevention and Control   (China)

Author keywords

Hypoxia; Non small cell lung cancer; Oxygen dependent degradation domain; P53; Solid tumor; Targeted therapy; TAT

Indexed keywords

HYBRID PROTEIN; PROCASPASE 3; PROTEIN P21; PROTEIN P53; RECOMBINANT PROTEIN;

APOPTOSIS; CANCER INHIBITION; CANCER TISSUE; CELL CYCLE ARREST; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OXYGEN TENSION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL CYCLE; CELL GROWTH PROCESSES; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENES, P53; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78751537820     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.1.13960     Document Type: Review

References (46)

1. Flehinger BJ, Kimmel M, Polyak T, Melamed MR. Screening for lung cancer, the Mayo lung project revisited. Cancer 1993; 72:1573-80.
2. Stinchcombe1 TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009; 6:233-41.
3. Hollstein M, Sidransky D, Vogrlstein B, Harris CC. p53 mutation in human cancers. Science 1991; 253:49-53.
4. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246:491-4.
5. Pellegata NS, Ranzani GN. The clinical significance of p53 mutations in human cancers. Eur J Histochem 1996; 40:273-82.
6. Weisz L, Oren M, Rotter V. Transcriptional regulation by mutant p53. Oncogene 2007; 26:2202-11.
7. Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2010; 2:1016.
8. Vogt U, Zaczek A, Klinke F, Granetzny A, Bielawski K, Falkiewicz B. p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. J Cancer Res Clin Oncol 2002; 128:141-7.
9. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure and lung cancer. Hum Mutat 2003; 21:229-39.
10. Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Piattoni S, et al. Plasma DNA, microsatellite alterations and p53 tumor mutations are associated with diseasefree survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinaryteam for thoracic oncology. J Thorac Oncol 2008; 3:365-73.
11. Brown JM. The hypoxic cell: a target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1999; 59:5863-70.
12. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 2004; 4:437-47.
13. Harris AL. Hypoxia-a key regulatory factor in tumor growth. Nat Rev Cancer 2002; 2:38-47.
14. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007; 67:4157-63.
15. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15:678-85.
16. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-1α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468-72.
17. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J 1998; 17:5085-94.
18. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996; 379:88-91.
19. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998; 273:6417-23.
20. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001; 85:881-90.
21. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc 2008; 83:584-94.
22. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in nonsmall cell lung cancer. Lung Cancer 2010; 69:1-12. DOI:10.1016/j.lungcan. 2009.12.009.
23. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005; 16:1391-7.
24. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, et al. Synthesis and Structure-activity relationships of 6, 7-disubstituted 4-anilinoquinoline- 3-carbonitriles the design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem 2003; 46:49-63.
25. Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007; 12:840-9.
26. Govindan R, Bogart J, Wang X, Liu D, Kratzke RA, Vokes EE. A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407-early evaluation of feasibility and toxicity. Proc Am Soc Clin Oncol 2008; 26:7518.
27. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26:3709-14.
28. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 2009; 10:28-35.
29. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6:491.
30. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:3238-47.
31. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically activeprotein into the mouse. Science 1999; 285:569-72.
32. Harada H, Hiraoka M, Kondoh SK. Antitumor effect of TAT-Oxygen-dependent degradation-Caspase-3 function protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 2002; 62:2013-8.
33. Zhao Y, Wu JH, Wu SP, Jia P, Tong Y, Wu X, et al. A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth. Cancer Lett 2009; 279:101-7.
34. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91:763-71.
35. Roth JA. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum Gene Ther 1996; 7:1013-30.
36. Wiman KG. Strategies for therapeutic targeting ofthe p53 pathway in cancer. Cell Death Differ 2006; 13:921-6.
37. Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ 2005; 12:942-61.
38. Snyder EL, Dowdy SF. Protein/peptide transduction domains: Potential to deliver large DNA molecules into cells. Curr Opin Mol Ther 2001; 3:147-52.
39. Ford KG, Souberbielle BE, Darling D, Farzaneh F. Protein transduction: an alternative to genetic intervention. Gene Ther 2001; 8:1-4.
40. Levy NS, Goldberg MA, Levy AP. Sequencing of the human vascular endothelial growth factor (VEGF) 3' untranslated region (UTR): conservation of five hypoxiainducible RNA-protein binding sites. Biochim Biophys Acta 1997; 1352:167-73.
41. Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ, Giaccia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14:6264-77.
42. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmicproapoptotic function of p53. Science 2005; 309:1732-5.
43. Alan GP, Reiner UJ. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999; 6:99-104.
44. Slade N, Moll UM. Mutational analysis of p53 in human tumors. In: Deb S, Deb SP. Methods in molecular biology: p53 protocols. Totowa: Humana Press Inc 2003; 231-43.
45. Chen MF, Keng PC, Shau HY, Wu CT, Hu YC, Liao SK, et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression Int. J Radia Onco Biol Phys 2006; 64:581-91.
46. McGinley JN, Knott KK, Thompson HJ. Semiautomated method of quantifying vasculature of 1-Methyl-1-nitrosourea-induced rat mammary carcinomas using immunohistochemical detection. J Histochem Cytochem 2002; 50:213-22.